About Vital Therapies (NASDAQ:VTL)
Vital Therapies, Inc. is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient's liver to regenerate to a healthy state, or to stabilize the patient until transplant. The ELAD System is a liver support system containing immortal human liver-derived cells, or VTL C3A cells. The Company initiated a Phase III clinical trial in severe acute alcoholic hepatitis (sAAH), referred to as VTL-308. Its VTL-308 is a randomized, open-label, multicenter, controlled, pivotal study, designed to evaluate the ELAD System in subjects with sAAH. It is based on pre-specified and post-hoc analyses of its VTI-208 phase III clinical trial in alcohol-induced liver decompensation (AILD). The Company's ELAD System consists of approximately four disposable ELAD C3A cell cartridges.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$1.19 per share
Price / Book5.13
Return on Equity-77.19%
Return on Assets-68.90%
Vital Therapies (NASDAQ:VTL) Frequently Asked Questions
What is Vital Therapies' stock symbol?
Vital Therapies trades on the NASDAQ under the ticker symbol "VTL."
How were Vital Therapies' earnings last quarter?
Vital Therapies Inc (NASDAQ:VTL) announced its quarterly earnings data on Tuesday, March, 13th. The company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by $0.04. During the same quarter in the prior year, the company posted ($0.37) EPS. View Vital Therapies' Earnings History.
When will Vital Therapies make its next earnings announcement?
Where is Vital Therapies' stock going? Where will Vital Therapies' stock price be in 2018?
1 brokers have issued 1 year price targets for Vital Therapies' stock. Their predictions range from $6.00 to $6.00. On average, they anticipate Vital Therapies' stock price to reach $6.00 in the next twelve months. View Analyst Ratings for Vital Therapies.
Who are some of Vital Therapies' key competitors?
Some companies that are related to Vital Therapies include Obseva (OBSV), MediciNova (MNOV), Zealand Pharma A/S - American Depositary Shares (ZEAL), BioCryst Pharmaceuticals (BCRX), Keryx Biopharmaceuticals (KERX), Zealand Pharma A/S (ZLDPF), Sinovac Biotech (SVA), Achaogen (AKAO), SIGA Technologies (SIGA), Synergy Pharmaceuticals (SGYP), Cytokinetics (CYTK), Aurinia Pharmaceuticals (AUPH), Inovio Pharmaceuticals (INO), Pharma Mar (PHMMF), Protagonist Therapeutics (PTGX), PDL Biopharma (PDLI), GTX (GTXI) and Paratek Pharmaceuticals (PRTK).
Who are Vital Therapies' key executives?
Vital Therapies' management team includes the folowing people:
- Faheem Hasnain, Chairman of the Board (Age 58)
- Russell J. Cox, Chief Executive Officer, Director (Age 54)
- Michael V. Swanson M.B.A., Chief Financial Officer (Age 55)
- Robert A. Ashley, Executive Vice President, Chief Technical Officer (Age 57)
- Duane D Nash M.D., Executive Vice President, Chief Business Officer (Age 46)
- Aron P. Stern M.B.A., Chief Administrative Officer (Age 61)
- Andrew Henry, Vice President - Clinical Operations (Age 50)
- Andrea Loewen-Rodriguez, Vice President - Regulatory Affairs and Quality Assurance (Age 47)
- Richard Murawski, Vice President - Manufacturing (Age 66)
- John Michael Dunn, General Counsel, Secretary (Age 63)
Has Vital Therapies been receiving favorable news coverage?
Headlines about VTL stock have trended somewhat positive this week, according to Accern. Accern identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vital Therapies earned a media sentiment score of 0.18 on Accern's scale. They also assigned media stories about the company an impact score of 47.15 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are Vital Therapies' major shareholders?
Vital Therapies' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Victory Capital Management Inc. (6.93%), BlackRock Inc. (2.35%), Millennium Management LLC (0.59%), Geode Capital Management LLC (0.46%), Renaissance Technologies LLC (0.16%) and Citadel Advisors LLC (0.09%). Company insiders that own Vital Therapies stock include Duane Nash, Faheem Hasnain, Jean Jacques Bienaime, John Michael Dunn, Muneer A Satter, Robert A Ashley and Terence E Winters. View Institutional Ownership Trends for Vital Therapies.
Which institutional investors are selling Vital Therapies stock?
Which institutional investors are buying Vital Therapies stock?
VTL stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Victory Capital Management Inc., Citadel Advisors LLC, BlueCrest Capital Management Ltd, Two Sigma Investments LP, Goldman Sachs Group Inc., Bank of Montreal Can and Geode Capital Management LLC. Company insiders that have bought Vital Therapies stock in the last two years include Duane Nash, Faheem Hasnain, Jean Jacques Bienaime, John Michael Dunn, Muneer A Satter, Robert A Ashley and Terence E Winters. View Insider Buying and Selling for Vital Therapies.
How do I buy shares of Vital Therapies?
Shares of VTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vital Therapies' stock price today?
One share of VTL stock can currently be purchased for approximately $6.10.
How big of a company is Vital Therapies?
Vital Therapies has a market capitalization of $252.10 million. The company earns $-52,070,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Vital Therapies employs 97 workers across the globe.
How can I contact Vital Therapies?
Vital Therapies' mailing address is 15010 AVENUE OF SCIENCE SUITE 200, SAN DIEGO CA, 92128. The company can be reached via phone at 858-673-6840 or via email at [email protected]
MarketBeat Community Rating for Vital Therapies (VTL)MarketBeat's community ratings are surveys of what our community members think about Vital Therapies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Vital Therapies (NASDAQ:VTL) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||3.00||2.50||2.67||2.67|
|Ratings Breakdown: ||0 Sell Rating(s)|
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$6.00||$6.00||$8.00||$8.00|
|Price Target Upside: ||1.64% downside||25.00% upside||66.67% upside||207.69% upside|
Vital Therapies (NASDAQ:VTL) Consensus Price Target History
Vital Therapies (NASDAQ:VTL) Analyst Ratings History
(Data available from 3/22/2016 forward)
Vital Therapies (NASDAQ:VTL) Earnings History and Estimates Chart
Vital Therapies (NASDAQ VTL) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Vital Therapies (NASDAQ:VTL) Earnings Estimates
2018 EPS Consensus Estimate: ($1.47)
2019 EPS Consensus Estimate: ($1.71)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Vital Therapies (NASDAQ:VTL)
No dividend announcements for this company have been tracked by MarketBeat.com
Vital Therapies (NASDAQ VTL) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 32.60%
Institutional Ownership Percentage: 25.99%
Vital Therapies (NASDAQ VTL) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/13/2017||Muneer A Satter||Director||Buy||100,000||$5.48||$548,000.00|| |
|12/11/2017||Muneer A Satter||Director||Buy||150,000||$4.89||$733,500.00|| |
|12/7/2017||Muneer A Satter||Director||Buy||50,000||$4.77||$238,500.00|| |
|9/14/2017||Muneer A Satter||Director||Buy||130,000||$4.01||$521,300.00|| |
|9/13/2017||Jean Jacques Bienaime||Director||Buy||10,000||$4.00||$40,000.00||65,119|| |
|9/8/2017||Muneer A Satter||Director||Buy||50,000||$3.53||$176,500.00|| |
|6/14/2017||John Michael Dunn||General Counsel||Buy||2,500||$3.09||$7,725.00||9,485|| |
|6/14/2017||Muneer A Satter||Director||Buy||20,000||$3.07||$61,400.00|| |
|6/14/2017||Terence E Winters||Chairman||Buy||10,000||$3.10||$31,000.00||194,966|| |
|6/13/2017||Muneer A Satter||Director||Buy||10,000||$3.03||$30,300.00|| |
|6/12/2017||Muneer A Satter||Director||Buy||30,000||$3.11||$93,300.00|| |
|6/9/2017||Robert A Ashley||Insider||Buy||2,000||$3.18||$6,360.00||2,000|| |
|6/8/2017||Duane Nash||President||Buy||3,900||$3.12||$12,168.00||8,224|| |
|6/7/2017||Muneer A Satter||Director||Buy||20,000||$3.20||$64,000.00|| |
|6/6/2017||Muneer A Satter||Director||Buy||10,000||$3.19||$31,900.00|| |
|3/27/2017||Muneer A Satter||Director||Buy||3,750,000||$4.00||$15,000,000.00|| |
|8/12/2016||Faheem Hasnain||Director||Buy||118,243||$5.92||$699,998.56||122,743|| |
|10/28/2015||Muneer A Satter||Director||Buy||400,000||$5.50||$2,200,000.00|| |
|10/26/2015||Cheryl Cohen||Director||Buy||3,500||$7.17||$25,095.00|| |
|10/26/2015||John Michael Dunn||General Counsel||Buy||9,385||$6.81||$63,911.85||9,385|| |
|9/10/2015||Jean Jacques Bienaime||Director||Buy||14,000||$3.08||$43,120.00||39,119|| |
|10/10/2014||Terence E Winters||CEO||Buy||1,360||$14.86||$20,209.60|| |
|10/8/2014||Duane Nash||Insider||Buy||100||$17.50||$1,750.00|| |
|10/8/2014||Lowell Sears||Director||Buy||1,429||$17.50||$25,007.50|| |
|6/3/2014||Muneer A Satter||Director||Buy||14,500||$13.16||$190,820.00|| |
|4/23/2014||Muneer A Satter||Director||Buy||360,966||$12.00||$4,331,592.00|| |
Vital Therapies (NASDAQ VTL) News Headlines
|Vital Therapies Announces VTL-308 Reaches Enrollment Target of 150 Subjects|
finance.yahoo.com - March 22 at 8:28 AM
|Options Traders Expect Huge Moves in Vital Therapies (VTL) Stock|
www.zacks.com - March 20 at 8:29 AM
|Vital Therapies (VTL) Lowered to Sell at Zacks Investment Research|
www.americanbankingnews.com - March 17 at 10:31 AM
|Edited Transcript of VTL earnings conference call or presentation 13-Mar-18 8:30pm GMT|
finance.yahoo.com - March 16 at 6:28 PM
|Vital Therapies Inc to Post Q1 2018 Earnings of ($0.36) Per Share, William Blair Forecasts (VTL)|
www.americanbankingnews.com - March 16 at 7:44 AM
|Vital Therapies Announces Fourth Quarter and Full Year 2017 Financial Results|
finance.yahoo.com - March 14 at 8:34 AM
|Vital Therapies (VTL) Announces Quarterly Earnings Results, Misses Expectations By $0.04 EPS|
www.americanbankingnews.com - March 13 at 9:14 PM
|Vital Therapies, Inc. to Host Earnings Call|
www.baystreet.ca - March 13 at 7:15 PM
|When Will Vital Therapies Inc (NASDAQ:VTL) Breakeven?|
finance.yahoo.com - March 13 at 8:27 AM
|Vital Therapies (VTL) to Release Earnings on Tuesday|
www.americanbankingnews.com - March 6 at 3:52 AM
|Vital Therapies Announces Upcoming Fourth Quarter and Full Year Financial Results Conference Call with Webcast and Participation in Upcoming Conference|
finance.yahoo.com - February 27 at 8:20 AM
|Vital Therapies (VTL) to Release Quarterly Earnings on Monday|
www.americanbankingnews.com - February 26 at 3:56 AM
|Vital Therapies Inc (VTL) Expected to Announce Earnings of -$0.30 Per Share|
www.americanbankingnews.com - February 18 at 7:20 PM
|-$0.30 Earnings Per Share Expected for Vital Therapies Inc (VTL) This Quarter|
www.americanbankingnews.com - February 1 at 9:12 PM
|Vital Therapies (VTL) Stock Rating Upgraded by BidaskClub|
www.americanbankingnews.com - February 1 at 12:30 AM
|Contrasting Halozyme Therapeutics (HALO) and Vital Therapies (VTL)|
www.americanbankingnews.com - January 21 at 1:16 AM
|Vital Therapies Inc (VTL) Expected to Post Earnings of -$0.30 Per Share|
www.americanbankingnews.com - January 15 at 9:14 PM
|Vital Therapies Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)|
finance.yahoo.com - January 5 at 10:40 AM
| Brokerages Expect Vital Therapies Inc (VTL) to Post -$0.30 EPS|
www.americanbankingnews.com - December 30 at 1:24 AM
|Vital Therapies, Inc. (VTL) Receives Average Rating of "Hold" from Brokerages|
www.americanbankingnews.com - December 19 at 3:36 AM
|Insider Buying: Vital Therapies, Inc. (VTL) Director Buys 100,000 Shares of Stock|
www.americanbankingnews.com - December 14 at 8:52 PM
| Analysts Expect Vital Therapies, Inc. (VTL) to Announce -$0.30 EPS|
www.americanbankingnews.com - December 12 at 11:14 PM
|Insider Buying: Vital Therapies, Inc. (VTL) Director Purchases 50,000 Shares of Stock|
www.americanbankingnews.com - December 11 at 8:50 PM
|Vital Therapies, Inc. (VTL) Director Muneer A. Satter Buys 150,000 Shares|
www.americanbankingnews.com - December 11 at 8:26 PM
|Vital Therapies Added to NASDAQ Biotechnology Index|
finance.yahoo.com - December 11 at 11:10 AM
|Vital Therapies (VTL) Earns Buy Rating from Raymond James Financial|
www.americanbankingnews.com - December 6 at 5:00 PM
| Analysts Expect Vital Therapies, Inc. (VTL) to Post -$0.30 EPS|
www.americanbankingnews.com - November 25 at 3:24 AM
|Vital Therapies, Inc. (VTL) Given Average Recommendation of "Hold" by Analysts|
www.americanbankingnews.com - November 24 at 3:56 AM
|Analyzing Stemline Therapeutics (STML) and Vital Therapies (VTL)|
www.americanbankingnews.com - November 23 at 11:40 PM
|ValuEngine Downgrades Vital Therapies, Inc. (VTL) to Strong Sell|
www.americanbankingnews.com - November 18 at 12:04 AM
|Vital Therapies to Webcast Presentation at Upcoming Investor Conference|
feeds.benzinga.com - November 8 at 8:50 AM
|Financial Analysis: Vital Therapies (VTL) & Xenetic Biosciences (XBIO)|
www.americanbankingnews.com - November 7 at 1:28 AM
|-$0.30 Earnings Per Share Expected for Vital Therapies, Inc. (VTL) This Quarter|
www.americanbankingnews.com - November 6 at 3:22 AM
|Vital Therapies (VTL) versus Its Rivals Head-To-Head Contrast|
www.americanbankingnews.com - October 31 at 3:06 PM
|Vital Therapies, Inc. (VTL) Downgraded to Sell at Zacks Investment Research|
www.americanbankingnews.com - October 31 at 11:53 AM
|Vital Therapies, Inc. (VTL) Given Average Recommendation of "Hold" by Brokerages|
www.americanbankingnews.com - October 30 at 1:22 AM
|Edited Transcript of VTL earnings conference call or presentation 25-Oct-17 8:30pm GMT|
finance.yahoo.com - October 28 at 8:34 AM
|Vital Therapies, Inc. (VTL) Announces Earnings Results|
www.americanbankingnews.com - October 26 at 9:06 PM
|Vital Therapies, Inc. (VTL) Set to Announce Earnings on Wednesday|
www.americanbankingnews.com - October 25 at 8:36 AM
|ValuEngine Upgrades Vital Therapies, Inc. (VTL) to "Sell"|
www.americanbankingnews.com - October 21 at 9:52 AM
| Analysts Anticipate Vital Therapies, Inc. (VTL) Will Post Earnings of -$0.30 Per Share|
www.americanbankingnews.com - October 17 at 12:52 PM
|BidaskClub Upgrades Vital Therapies, Inc. (VTL) to Strong-Buy|
www.americanbankingnews.com - October 5 at 11:20 PM
|Vital Therapies, Inc. (VTL) Receives Consensus Rating of "Hold" from Brokerages|
www.americanbankingnews.com - October 5 at 10:20 PM
|Vital Therapies, Inc. (VTL) Stock Rating Lowered by Zacks Investment Research|
www.americanbankingnews.com - October 5 at 6:58 PM
|Reviewing Vital Therapies (VTL) and The Competition|
www.americanbankingnews.com - October 5 at 12:16 AM
|All You Need To Know About Vital Therapies Inc’s (VTL) Risks|
finance.yahoo.com - October 3 at 2:44 PM
|Is It Too Late To Buy Vital Therapies Inc (VTL)?|
finance.yahoo.com - September 16 at 10:17 AM
|Insider Buying: Vital Therapies, Inc. (VTL) Director Buys 10,000 Shares of Stock|
www.americanbankingnews.com - September 14 at 11:56 PM
|Vital Therapies, Inc. (VTL) Director Muneer A. Satter Purchases 130,000 Shares|
www.americanbankingnews.com - September 14 at 10:52 PM
|Vital Therapies, Inc. (VTL) Director Buys $176,500.00 in Stock|
www.americanbankingnews.com - September 12 at 7:54 PM
Vital Therapies (NASDAQ:VTL) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Vital Therapies (NASDAQ:VTL) Income Statement, Balance Sheet and Cash Flow Statement
Vital Therapies (NASDAQ VTL) Stock Chart for Thursday, March, 22, 2018